Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavis, Niall F-
dc.contributor.authorJack, Gregory S-
dc.contributor.authorWitjes, W P-
dc.contributor.authorBjartell, A-
dc.contributor.authorCaris, C-
dc.contributor.authorPatel, A-
dc.contributor.authorde la Taille, A-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorTubaro, A-
dc.identifier.citationWorld Journal of Urology 2019; 37(5): 873-878-
dc.description.abstractA cost minimisation analysis compares the costs of different interventions' to ascertain the least expensive over time. We compared different prostate targeted drug treatments with TURP to identify the optimal cost saving duration of a medical therapy for symptomatic benign prostatic enlargement (BPE). The Evolution registry is a prospective, multicentre registry, conducted by the European Association of Urology Research Foundation (EAUrf) for 24 months in 5 European countries. Evolution was designed to register the management of symptomatic BPE in clinical practice settings in 5 European countries. Direct cost evaluation associated with prostate targeted medical therapies and TURP was also recorded and analysed. In total, 1838 men were enrolled with 1246 evaluable at 24 months. Medical therapies were more cost saving than TURP for treatment durations ranging from 2.9 to 70.4 years. Cost saving depended on both medication class and individual country assessed. Daily tamsulosin monotherapy was more cost saving than TURP for ≤ 13.9 years in Germany compared to ≤ 32.7 years in Italy. Daily finasteride monotherapy was more cost saving for ≤ 5.9 years in France compared to ≤ 36.9 years in Spain. Combination therapy was more cost saving for ≤ 5.9 years for Italian patients versus ≤ 13.8 years in Germany. BPE medical management was more cost saving than TURP for different specific treatment durations. Information from this study will allow clinicians to convey medical and surgical costs over time, to both patients and payors alike, when considering BPE treatment.-
dc.subjectBenign prostatic enlargement-
dc.subjectBenign prostatic hyperplasia-
dc.subjectCost minimisation analysis-
dc.titleMedical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.-
dc.typeJournal Article-
dc.identifier.journaltitleWorld Journal of Urology-
dc.identifier.affiliationDepartment of Urology, Lund University, Skane Hospital, Malmö, Sweden..en
dc.identifier.affiliationDepartment of Urology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationEAU Research Foundation, P.O. Box 30016, 6803 AA, Arnhem, The Netherlandsen
dc.identifier.affiliationDepartment of Urology, Spire London East Hospital, Roding Lane South, Redbridge, Essex, Ilford, IG4 5PZ, UK-
dc.identifier.affiliationDepartment of Urology, Assistance Publique des Hopitaux de Paris, 54 av du Mal de Lattre de Tassigny, 94000, Créteil, France-
dc.identifier.affiliationDepartment of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy-
dc.type.austinComparative Study-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 2, 2021

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.